Novo Nordisk’s New Diabetes Combo Shows Potential To Best Lilly’s Mounjaro
Fierce Competition In Diabetes And Obesity Expected
Executive Summary
New Phase II data shows combination of semaglutide plus a novel amylin analog outperforms semaglutide alone, and could surpass Lilly’s Mounjaro in helping weight loss in diabetes patients.
You may also be interested in...
Lilly Focuses On ‘Traditional’ Approval For Donanemab, Increased Mounjaro Production
Mounjaro’s fourth quarter sales disappointed some analysts, but the launch remains off to a strong start. Donanemab now on track for full approval in Alzheimer’s, CEO Ricks pledges.
The Top Five Pharma Stories Of 2022
Scrip has taken a look back at five of the biggest story themes in no particular order of 2022 where once again the biopharma industry had plenty on its plate.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Axsome gets broad label for new depression drug; Argenx CEO on Vyvgart’s success; Chinese firms delist from US; solid results for Novo Nordisk’s new diabetes combo; and women leaders herald change at foreign firms in India.